Send us Fan Mail

Lymphomas represent the most common group of haematological malignancies, encompassing a broad spectrum of biologically and clinically distinct entities. Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) together account for the majority of B-cell non-Hodgkin lymphomas encountered in clinical practice. The therapeutic landscape across all three entities has undergone a profound transformation in recent years, driven by advances in molecular classification, the emergence of CAR-T cell therapies, bispecific antibodies, and targeted agents, fundamentally challenging established treatment paradigms and raising new questions around sequencing, patient selection, and long-term outcomes.

Our guest today is Professor Mats Jerkeman, senior consultant haematologist and professor at Lund University Hospital, Sweden, one of Scandinavia's leading experts in lymphoma. Professor Jerkeman has extensive clinical and research experience spanning the full spectrum of B-cell lymphomas, with a particular focus on translational research, novel immunotherapy approaches, and Nordic collaborative trials. He is an active contributor to the Nordic Lymphoma Group and has been instrumental in shaping lymphoma management guidelines at both national and international levels.

MAT-SE-2600313 (ver.2) 05.2026

Send us Fan Mail

Immune thrombocytopenia, the ITP is increasingly recognized as a complex immune‑mediated disease rather than just a disorder of low platelets. This episode, explores new developments in ITP, focusing on the complex immune disorder as the underlying mechanism of ITP and how immunological mechanisms translate into the diverse clinical manifestations seen in clinical practice.

Expert guests in this episode are:

Henrik Frederiksen, is a Consultant Hematologist and Clinical Professor at Odense University Hospital and University of Southern Denmark. He is an expert in benign hematology, particularly immune thrombocytopenia (ITP), and autoimmune hemolytic anemia (AIHA), and is an active contributor to EHA guideline development.

Rick Kapur, MD, PhD, MSc, is a research group leader at Sanquin Blood Supply Foundation, Department Research, Amsterdam, The Netherlands. His research focuses on pathophysiology of immune-mediated disorders of platelets (e.g. immune thrombocytopenia; ITP) and endothelium (e.g. Transfusion-related acute lung injury; TRALI).

Sanquin is the national blood service for Netherlands, knowledge institute in the field of blood, and internationally renowned research institute in the fields of blood transfusion medicine and immunology. This knowledge is applied for development and production of a range of pharmaceutical and diagnostic services.

MAT-BE-2600181 (ver.1) Feb 2026

Send us Fan Mail

Gaucher disease is a rare lysosomal storage disorder that presents with varying prevalence and management approaches across Nordic countries. Despite geographical proximity, these countries show notable differences in disease presentation, diagnostic approaches, and patient care pathways. This episode explores these unique challenges and opportunities while identifying potential areas for collaborative improvement in patient care across Scandinavia. Tune in to discover how this rare condition shapes healthcare approaches in the Nordic region.

Featured Experts:

Professor Allan Lund: Board-certified specialist in paediatrics with expert training in rare paediatric metabolism. He currently works at Rigshospitalet in Copenhagen, Denmark where he is the leader of Center for Rare metabolic diseases for children and adults. He has spent several years researching, diagnosing, and treating patients with different rare metabolic disorders.

Dr. Per Ole Iversen: Medical doctor, specialist in internal medicine and hematology, senior consultant at the Department of Hematology at Oslo University Hospital (OUS), and professor of clinical nutrition at the University of Oslo. He has a particular interest in Gaucher disease and treats the majority of Norwegian Gaucher patients

Among the Nordic countries, Denmark stands out as the only nation without a current dedicated Gaucher Patient Advocacy Group (PAG). However, Danish Gaucher patients are represented through the national rare disease umbrella organization "Sjældne Diagnoser" (Rare Diseases Denmark). This organization serves as a collective voice for patients with rare conditions, including those affected by Gaucher disease. In contrast, the other Nordic countries - Sweden, Norway, Finland, and Iceland - each have their own dedicated Gaucher PAGs. These organizations specifically focus on supporting Gaucher patients and their families, raising awareness, and advocating for their needs within their respective healthcare systems.

MAT-BE-2500772 (ver.1) Jul 2025